Comprehensive Comparisons of Different Treatments for Active Graves Orbitopathy: A Systematic Review and Bayesian Model–Based Network Meta-Analysis
Authors' conclusion
Teprotumumab emerges as potentially the most effective treatment for reducing inflammation and increasing overall response rates when compared with no treatment; oral mycophenolate combined with IVGCs appears to be the best for improving proptosis. While some treatments raise safety concerns due to reported adverse events, oral methotrexate combined with IVGCs appear to offer a favorable balance between efficacy and safety among the evaluated treatments.
Study context
- Population
- Randomized controlled trials (RCTs) of treatments for active thyroid eye disease, searched until November 20, 2024
- Comparison
- Different treatments for active Graves orbitopathy vs no treatment
- Outcome
- Overall response rate, CAS, proptosis, diplopia and adverse events
Methodological detailsBayesian framework
- Bayesian framework
Pooled result
As reported in the abstract
Overall response rate, CAS, proptosis, diplopia
Teprotumumab vs No treatmentRelative risk (overall response rate) (95% CI)
Overall response rate, CAS, proptosis, diplopia
5.5(2.3–16)
Teprotumumab vs No treatmentEstimate (95% CI)
Comparator not stated for MD
MD (CAS) −1.57(−3.81 to 0.68)
Comparator not stated for MD
MD (proptosis) −2.29(−2.73 to −1.86)
Original publication
Comprehensive Comparisons of Different Treatments for Active Graves Orbitopathy: A Systematic Review and Bayesian Model–Based Network Meta-Analysis. J Clin Endocrinol Metab. Published 16 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →